

Allan J Barnes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1331555/publications.pdf>

Version: 2024-02-01

28
papers

935
citations

430874

18
h-index

501196

28
g-index

28
all docs

28
docs citations

28
times ranked

1088
citing authors

#	ARTICLE	IF	CITATIONS
1	Free and Glucuronide Urine Cannabinoids after Controlled Smoked, Vaporized and Oral Cannabis Administration in Frequent and Occasional Cannabis Users. <i>Journal of Analytical Toxicology</i> , 2020, 44, 651-660.	2.8	12
2	Effects of the Psychedelic Amphetamine MDA (3,4-Methylenedioxyamphetamine) in Healthy Volunteers. <i>Journal of Psychoactive Drugs</i> , 2019, 51, 108-117.	1.7	13
3	Optimization of recombinant β -glucuronidase hydrolysis and quantification of eight urinary cannabinoids and metabolites by liquid chromatography tandem mass spectrometry. <i>Drug Testing and Analysis</i> , 2018, 10, 518-529.	2.6	22
4	Recent Self-Reported Cannabis Use Is Associated With the Biometrics of Delta-9-Tetrahydrocannabinol. <i>Journal of Studies on Alcohol and Drugs</i> , 2018, 79, 441-446.	1.0	21
5	Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial. <i>PLoS ONE</i> , 2018, 13, e0190768.	2.5	88
6	The acute effect of cannabis on plasma, liver and brain ammonia dynamics, a translational study. <i>European Neuropsychopharmacology</i> , 2017, 27, 679-690.	0.7	13
7	On-site oral fluid Δ^9 -tetrahydrocannabinol (THC) screening after controlled smoked, vaporized, and oral cannabis administration. <i>Forensic Toxicology</i> , 2017, 35, 133-145.	2.4	13
8	Free and Glucuronide Whole Blood Cannabinoids' Pharmacokinetics after Controlled Smoked, Vaporized, and Oral Cannabis Administration in Frequent and Occasional Cannabis Users: Identification of Recent Cannabis Intake. <i>Clinical Chemistry</i> , 2016, 62, 1579-1592.	3.2	139
9	MDMA Impairs Response to Water Intake in Healthy Volunteers. <i>Advances in Pharmacological Sciences</i> , 2016, 2016, 1-11.	3.7	6
10	A preliminary evaluation of the relationship of cannabinoid blood concentrations with the analgesic response to vaporized cannabis. <i>Journal of Pain Research</i> , 2016, Volume 9, 587-598.	2.0	38
11	Simultaneous quantification of buprenorphine, naloxone and phase I and II metabolites in plasma and breastmilk by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography A</i> , 2016, 1446, 70-77.	3.7	19
12	Maternal Buprenorphine Maintenance and Lactation. <i>Journal of Human Lactation</i> , 2016, 32, 675-681.	1.6	31
13	Simultaneous quantification of 11 cannabinoids and metabolites in human urine by liquid chromatography tandem mass spectrometry using WAX-S tips. <i>Analytical and Bioanalytical Chemistry</i> , 2016, 408, 6461-6471.	3.7	49
14	Quantification of cannabinoids and their free and glucuronide metabolites in whole blood by disposable pipette extraction and liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography A</i> , 2016, 1453, 34-42.	3.7	48
15	Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings. <i>Drug and Alcohol Dependence</i> , 2016, 161, 298-306.	3.2	70
16	Validation of an ELISA Synthetic Cannabinoids Urine Assay. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 661-669.	2.0	20
17	Plasma Cannabinoid Pharmacokinetics After Controlled Smoking and <i>Ad libitum</i> Cannabis Smoking in Chronic Frequent Users. <i>Journal of Analytical Toxicology</i> , 2015, 39, 580-587.	2.8	40
18	Cocaine and metabolite concentrations in DBS and venous blood after controlled intravenous cocaine administration. <i>Bioanalysis</i> , 2015, 7, 2041-2056.	1.5	24

#	ARTICLE	IF	CITATIONS
19	Oral fluid cannabinoids in chronic frequent cannabis smokers during <i>ad libitum</i> cannabis smoking. <i>Drug Testing and Analysis</i> , 2015, 7, 494-501.	2.6	14
20	Performance characteristics of an ELISA screening assay for urinary synthetic cannabinoids. <i>Drug Testing and Analysis</i> , 2015, 7, 467-474.	2.6	29
21	Quantification of 11-Nor-9-Carboxy- δ^9 -Tetrahydrocannabinol in Human Oral Fluid by Gas Chromatography-Tandem Mass Spectrometry. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 225-233.	2.0	14
22	3,4-Methylenedioxyamphetamine (MDMA) and metabolites disposition in blood and plasma following controlled oral administration. <i>Analytical and Bioanalytical Chemistry</i> , 2014, 406, 587-599.	3.7	21
23	Evaluation of a homogenous enzyme immunoassay for the detection of synthetic cannabinoids in urine. <i>Forensic Science International</i> , 2014, 241, 27-34.	2.2	46
24	MDMA and Metabolite Disposition in Expecterated Oral Fluid After Controlled Oral MDMA Administration. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 602-608.	2.0	17
25	Excretion of Methadone in Sweat of Pregnant Women Throughout Gestation After Controlled Methadone Administration. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 497-503.	2.0	12
26	Disposition of MDMA and Metabolites in Human Sweat Following Controlled MDMA Administration. <i>Clinical Chemistry</i> , 2009, 55, 454-462.	3.2	32
27	Excretion of Methamphetamine and Amphetamine in Human Sweat Following Controlled Oral Methamphetamine Administration. <i>Clinical Chemistry</i> , 2008, 54, 172-180.	3.2	43
28	Sensitivity, Specificity, and Efficiency in Detecting Opiates in Oral Fluid with the Cozart(R) Opiate Microplate EIA and GC-MS Following Controlled Codeine Administration. <i>Journal of Analytical Toxicology</i> , 2003, 27, 402-406.	2.8	41